Aug 09, 2021 4:01 pm EDT Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
Aug 02, 2021 6:00 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 02, 2021 8:30 am EDT Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
Jul 02, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jul 01, 2021 4:30 pm EDT Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
Jun 07, 2021 10:30 am EDT Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
Jun 04, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 14, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 13, 2021 4:01 pm EDT Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
May 10, 2021 8:30 am EDT Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer